Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN™️, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN™️ drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States.
In addition to its PFN™️ Program, Tryp is also developing TRP-1001, an oral formulation of razoxane for the treatment of soft tissue sarcoma. Soft tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for Orphan Drug status.
The TRYP Management team has decades of experience building successful pharmaceutical and biotech companies together, and bring a balanced combination of capital markets experience, Big Pharma and FDA expertise (having successfully brought drugs to market), and a track record of building profitable public companies.
James Kuo, Chief Executive Officer
William Garner, Executive Chairman
Tom D’Orazio, Chief Operating Officer
Dr. Jim Gilligan, President & Chief Science Officer
TRYP’s PFN™ Program
Tryp’s PFN™ program is focused on developing orally-delivered drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs that are currently in the market or are in development.
TRP-8802 | Fibromyalgia
Chronic and debilitating CNS/neurobiological disorder. The fibromyalgia treatment market is estimated to surpass US$3.6B by 2026.
TRP-1001 | Razoxane (Soft Tissue Sarcomas)
Oncology is the leading therapeutic category and represented 25% of all drug sales in 2018, which equated to ~US$151B in 2018.